RLFTD - RLFTD STOCK NEWS

Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential for an additional $46.5 million in milestone and royalty payments. The transition to a revenue-based royalty stream model is expected to deliver earlier returns and enhanced predictability to Relief Therapeutics.

Relief Therapeutics announces the results of its Annual General Meeting (AGM) of shareholders. Certain proposed items by the board of directors did not receive majority approval, possibly due to differences in opinion on the future development of the company. The rejected proposals will be reviewed and analyzed. The AGM approved the annual report and financial statements for 2022, but denied discharge to the board of directors and executive committee for their activities in 2022. The capital band and conditional share capital remain unchanged. Most proposed amendments to the Articles of Association were approved, except for compensation-related amendments. Compensation proposals for board members and the executive committee were rejected. Existing board members were re-elected, including Dr. Raghuram Selvaraju as chairman. The nomination and compensation committee, independent voting rights representative, and auditors were also re-elected.

Relief Therapeutics Holding SA has announced an increase in its share capital from 4.62 billion to 5.62 billion shares by issuing 1 billion new shares, fully subscribed by its subsidiary, Relief Therapeutics International SA. These new shares will be listed on the SIX Swiss Exchange around December 22, 2022. Following this issuance, Relief expects about 1.2 billion shares to be held in treasury for future financing transactions, while the outstanding shares will remain unchanged until placement.

Relief Therapeutics announces leadership changes with Jack Weinstein appointed as CEO and Jeremy Meinen as CFO. Effective immediately, Weinstein aims to enhance the company's long-term strategy following the launch of their first product, PKU GOLIKE. Meinen, who has been with Relief since 2020, now takes on more responsibility in driving financial growth. These appointments come after the settlement of litigation with NRx Pharmaceuticals, signaling a strategic shift for Relief to focus on expanding its operations in the biopharmaceutical sector.

Relief Therapeutics announced the filing of Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of ordinary shares in the form of American Depositary Shares (ADSs). Details regarding the number and pricing of the ADSs are yet to be determined. The company plans to list these ADSs on the NASDAQ under the symbol RLFT. The offering will only proceed with an effective prospectus.